Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Temperature Controlled Laminar Airflow (TLA) on Rhinitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Airsonett AB.
Recruitment status was  Active, not recruiting
Croel AB
Commitum AB
Information provided by:
Airsonett AB Identifier:
First received: September 29, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

The purpose of this study is to determine whether clean air administered to the breathing zone with Temperature controlled Laminar Airflow (TLA) during night is effective as add on treatment in patients with perennial allergic asthma.

Condition Intervention Phase
Device: Protexo (Temperature controlled Laminar Airflow (TLA))
Device: Placebo TLA
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Temperature Controlled Laminar Airflow (TLA) on Rhinitis Quality of Life (RQLQ)

Further study details as provided by Airsonett AB:

Primary Outcome Measures:
  • Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) [ Time Frame: Week 0, 4, 12, 24, 36 and 52 ] [ Designated as safety issue: No ]

Enrollment: 14
Study Start Date: February 2008
Estimated Study Completion Date: February 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Temeperature controlled Laminar Airflow
Active treatment with Temperature controlled Laminar Airflow (TLA).
Device: Protexo (Temperature controlled Laminar Airflow (TLA))
Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA)
Other Name: Protexo
Placebo Comparator: Placebo TLA
Placebo TLA treatment
Device: Placebo TLA
Placebo TLA (without filtration and TLA function)

Detailed Description:

Exposure to inhaled allergens is a pathogenetic factor in allergic asthma. However, physical, chemical and combined methods aiming to reduce airborne allergen levels have shown little or no effect in reducing asthma symptoms in people who are sensitive to perennial allergens.

Aims and objectives: This study aims to investigate treatment with Temperature regulated Laminar Airflow (TLA) with a very low particle concentration directed to the breathing zone of subjects with allergic asthma during night sleep. The hypothesis is that the decreased allergen exposure during the night will have a positive effect on the Rhinoconjunctivitis Quality of life Questionnaire (RQLQ).

Method: This is a double blind, randomized 52 week parallel trial comparing active and placebo treatment with TLA. For ethical reasons the randomization is 2 to 1 for active and placebo treatment, respectively. A 2 weeks run-in period is inserted between inclusion and randomization. First 12 weeks an unchanged maintenance medication will be kept and week 13-52 medication will be modified to obtain asthma control according to international guidelines (GINA). After inclusion, run-in, randomization and baseline measurements active/placebo treatment with AA will be implemented over 52 weeks.


Ages Eligible for Study:   7 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Consent to participate voluntarily.
  • Willing and able to comply with the study specific procedures.
  • Signed Informed Consent prior to any study procedure.
  • Perennial allergic asthma
  • Age 7 through 70 years at time of randomization.
  • A miniAQLQ/PAQLQ score of ≤ 5.5.
  • Sensitive to pet allergen and/or house dust mites as demonstrated by changed to RAST 0.70 or positive skin prick test (wheal reaction similar to histamine control).
  • Daily maintenance dose of at least ICS >=200µg/day of budesonide or >=100µg/day of fluticasone since at least 6 months
  • Features of partly controlled asthma according to GINA

Exclusion Criteria:

  • Current smoker (Non-smoker is defined as abstinent since > 1 year). Children: Parents'indoor smoking.
  • Participation in another allergen avoidance program
  • Participation in drug trial the preceding 3 months
  • Multiple chemical sensitivity (e.g. paint, petrol, perfumes) as primary etiology
  • Allergen injection or sublingual treatment in the preceding 2 years
  • ICS ≥1200µg/day of budesonide or 1000µg/day of fluticasone
  • Significant cardiovascular disease
  • Participation in the present trial of a family member within the same household
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00986726

Allergicentrum, University Hospital of Linkoeping
Linkoeping, Sweden, SE 581 85
Sponsors and Collaborators
Airsonett AB
Croel AB
Commitum AB
Principal Investigator: Olof Zetterstrom, PhD, MD Allergy center, University Hospital of Linköping, Sweden
  More Information

No publications provided

Responsible Party: Prof. Olof Zetterström, Responsible investigator, Allergicentrum, University Hospital of Linkoeping, Sweden Identifier: NCT00986726     History of Changes
Other Study ID Numbers: Air 3-03-03, Main protocol Air 3-03 (4A)
Study First Received: September 29, 2009
Last Updated: September 29, 2009
Health Authority: Sweden: Medical Products Agency
Sweden: Regional Ethical Review Board

Keywords provided by Airsonett AB:
Temperature regulated Laminar Airflow
Perennial allergy
Environmental control
Paediatric Asthma Quality of Life Questionnaire (PAQLQ) processed this record on November 25, 2014